Much as immune escape through tumor CD19 loss and lineage switch may conceal tumor cells from CAR T, our findings demonstrate that tumor-induced shifts in the microenvironment can markedly alter the ability of CAR T cells to effectively engage and destroy tumor cells. This evidence concerns the gene CD19 and neoplasm.